Reform of drug regulation--beyond an independent drug-safety board. Ray WA, Stein CM (2006) N Engl J Med 354: 194-201 Evaluating drugs after their approval for clinical use. Ray WA, Griffin MR, Avorn J (1993) N Engl J Med 329: 2029-32 Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ (2018) Lancet Oncol 19: 1579-1589 The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes. Behr ER, January C, Schulze-Bahr E, Grace AA, Kääb S, Fiszman M, Gathers S, Buckman S, Youssef A, Pirmohamed M, Roden D (2013) Eur Heart J 34: 1958-63 Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Tatonetti NP, Denny JC, Murphy SN, Fernald GH, Krishnan G, Castro V, Yue P, Tsao PS, Tsau PS, Kohane I, Roden DM, Altman RB (2011) Clin Pharmacol Ther 90: 133-42 Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors. Grouthier V, Lebrun-Vignes B, Glazer AM, Touraine P, Funck-Brentano C, Pariente A, Courtillot C, Bachelot A, Roden DM, Moslehi JJ, Salem JE (2018) Heart 104: 1859-1863 Adherence to disease-modifying antirheumatic drugs and the effects of exposure misclassification on the risk of hospital admission. Grijalva CG, Kaltenbach L, Arbogast PG, Mitchel EF, Griffin MR (2010) Arthritis Care Res (Hoboken) 62: 730-4 Response to 'Use of an algorithm for identifying hidden drug-drug interactions in adverse event reports' by Gooden et al. Tatonetti NP, Denny JC, Altman RB (2013) J Am Med Inform Assoc 20: 591 Detecting adverse events using information technology. Bates DW, Evans RS, Murff H, Stetson PD, Pizziferri L, Hripcsak G (2003) J Am Med Inform Assoc 10: 115-28 Policy and the future of adverse event detection using information technology. Bates DW, Evans RS, Murff H, Stetson PD, Pizziferri L, Hripcsak G (2003) J Am Med Inform Assoc 10: 226-8 Clinical assessment of serious adverse events in children receiving 2009 H1N1 vaccination. Pahud BA, Williams SE, Dekker CL, Halsey N, Larussa P, Baxter RP, Klein NP, Marchant CD, Sparks RC, Jakob K, Aukes L, Swope S, Barnett E, Lewis P, Berger M, Dreskin SC, Donofrio PD, Sejvar JJ, Slade BA, Gidudu J, Vellozzi C, Edwards KM (2013) Pediatr Infect Dis J 32: 163-8 Biologically plausible and evidence-based risk intervals in immunization safety research. Rowhani-Rahbar A, Klein NP, Dekker CL, Edwards KM, Marchant CD, Vellozzi C, Fireman B, Sejvar JJ, Halsey NA, Baxter R, Risk Interval Working Group of the Clinical Immunization Safety Assessment Network (2012) Vaccine 31: 271-7 An algorithm developed using the Brighton Collaboration case definitions is more efficient for determining diagnostic certainty. Joshi D, Alsentzer E, Edwards K, Norton A, Williams SE (2014) Vaccine 32: 3469-72 Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Sarnes E, Crofford L, Watson M, Dennis G, Kan H, Bass D (2011) Clin Ther 33: 1413-32 Assessment of adverse drug events among patients in a tertiary care medical center. Johnston PE, France DJ, Byrne DW, Murff HJ, Lee B, Stiles RA, Speroff T (2006) Am J Health Syst Pharm 63: 2218-27
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.